Egypt

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.

J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Drawing references from the EU and US guidelines for decentralized clinical trials, the Egyptian FDA has framed draft requirements that sponsors should consider when planning to use off-site nurses in their drug and medical device studies.

Drawing references from the EU and US guidelines for decentralized clinical trials, the Egyptian FDA has framed draft requirements that sponsors should consider when planning to use off-site nurses in their drug and medical device studies.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-five documents have been posted on the tracker since its last update.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Egypt has become the latest market in which Alvotech has received approval for its AVT02 biosimilar adalimumab rival to Humira. The product will be marketed by MENA partner Bioventure.

Chinese biopharma Mabwell has formed licensing agreements in Pakistan and Egypt to roll out its denosumab biosimilars.

Under two developments in June, Egypt’s drug regulator can now be fully involved in the work of the International Council for Harmonisation, and it can incorporate the United States Pharmacopeia and the National Formulary standards into the Egyptian Pharmacopoeia.

The quality of analytical data obtained so far and accepted by the German Federal Ministry of Health’s Paul-Ehrlich Institute has been praised as part of the step forward.

The European Medicines Agency has OKd more production sites for the manufacture of vaccines destined for the EU, the US and Australia have warned against taking ivermectin to protect against SARS-CoV-2 infection, and Italy has dismissed some ‘fake news’ about vaccine approvals.

Hikma and GSK have agreed not to proceed with a deal being explored by the two firms that would have seen Hikma acquire a majority stake in the firm’s pharmaceutical and consumer health business in Egypt and Tunisia.